ARS Pharmaceuticals (SPRY) Return on Equity (2022 - 2025)
Historic Return on Equity for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 0.53%.
- ARS Pharmaceuticals' Return on Equity fell 2400.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year decrease of 2400.0%. This contributed to the annual value of 0.03% for FY2024, which is 2500.0% up from last year.
- Latest data reveals that ARS Pharmaceuticals reported Return on Equity of 0.53% as of Q3 2025, which was down 2400.0% from 0.28% recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Return on Equity ranged from a high of 0.01% in Q4 2024 and a low of 0.53% during Q3 2025
- Moreover, its 4-year median value for Return on Equity was 0.24% (2023), whereas its average is 0.2%.
- Per our database at Business Quant, ARS Pharmaceuticals' Return on Equity skyrocketed by 2800bps in 2024 and then crashed by -2400bps in 2025.
- ARS Pharmaceuticals' Return on Equity (Quarter) stood at 0.13% in 2022, then tumbled by -119bps to 0.29% in 2023, then soared by 95bps to 0.01% in 2024, then tumbled by -3865bps to 0.53% in 2025.
- Its Return on Equity was 0.53% in Q3 2025, compared to 0.28% in Q2 2025 and 0.11% in Q1 2025.